Drug Approval | July 29, 2024
Briefs: Indoco Remedies and Alembic Pharmaceuticals
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
The inspection was concluded with two 483 observations
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Subscribe To Our Newsletter & Stay Updated
